WHAT IS CLAIMED IS:

1. A compound having a structural Formula I,

$$Z \longrightarrow (CH_2)_m \longrightarrow \begin{bmatrix} C & R^{1a} & X & A \\ & & &$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

E is: O, S or NR¹⁴;

\ _Y_

10

W is:

R⁴ R⁵, hydrogen, C₁-C₆ alkyl. (CH₂)_n·C₃-C₆ cycloalkyl, haloalkyl or acyl;

Q is: $-C(O)OR^6$ or R^{6A} :

15 X is: a bond, C, O, S or $S[O]_p$:

Y is: a bond. S. C or O:

Z is: a) aliphatic group,

20 b) aryl,

- c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N. O or S.
- d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,

- e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and
- f) heterocyclyl:

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R¹⁵;

m and n' are each independently: 0, 1, 2, 3 or 4;

n is: 0, 1, 2 or 3;

10 p is: 1 or 2;

r is: 1, 2, 3 or 4:

v is: 1 or 2;

 R^1 is: hydrogen, wherein when Z is phenyl or naphthyl and R^2 is H, R^1 is not H,

15 haloalkyl,

C₁-C₆ alkyl,

C₁-C₆ alkyl-C₁-C₆ alkoxy,

C₁-C₆ alkyl-aryl,

C2-C6 alkenyl.

20 C₂-C₆ alkynyl,

 $(CH_2)_n \cdot C_3 \cdot C_6$ cycloalkyl,

 C_1 - C_6 alkoxy,

aryl, or

R¹ and R² together being a 5- to 8-membered heterocyclyl ring, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R¹⁵:

R^{1a} and R^{1b} are each independently:

hydrogen.

oil C1-C6 alkyl, or

 R^1 and R^{1a} , R^1 and R^{1b} , R^2 and R^{1a} , R^2 and R^{1b} or R^{1a} and R^{1b} together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R^{1a} and R^{1b} is not hydrogen;

5 R² is: hydrogen,

haloalkyl,

C₁-C₆ alkyl,

C₁-C₆ alkyl-C₁-C₆ alkoxy,

C₁-C₆ alkyl-aryl,

10 C₂-C₆ alkenyl,

C₂-C₆ alkynyl,

 $(CH_2)_n \cdot C_3 - C_6$ cycloalkyl,

C₁-C₆ alkoxy,

aryl, or

15 R¹ and R² together being a 5- to 8-membered heterocyclyl ring, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R¹⁵;

R^{2a} is: hydrogen, halo or C₁-C₆ alkyl and wherein R² and R^{2a} together being a 3- to 8membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from R¹⁵;

R³ is: hydrogen,

halo,

25 cyano.

30

haloalkyl,

C₁-C₆ alkyl,

 $(CH_2)_n \cdot C_3 - C_6$ cycloalkyl.

(C₁-C₄ alkyl)-heterocyclyl. wherein the heterocyclyl being optionally substituted with oxo.

 $(C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9$, and

wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R¹⁵;

R⁴ and R⁵ are each independently:

5 hydrogen,

halo,

C₁-C₆ alkyl

C₁-C₆ alkoxy;

aryloxy;

 $N(R^8)_2$

SR⁸ or

R⁴ and R⁵ together being a 3- to 8-membered ring;

R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl;

15

 R^{6A} is: carboxamide, C_1 - C_3 .alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

R⁷ is: hydrogen or C₁-C₆ alkyl;

20 R⁸ and R⁹ are each independently:

hydrogen, C_1 - C_6 alkyl, aryl, heteroaryl, or heterocyclyl, and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano. hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo. C_1 - C_6 alkyl and C_1 - C_6 alkoxy;

R¹⁴ is: hydrogen, aryl, C₁-C₆ alkyl, or C₁-C₆ alkyl-COOR⁶, and wherein aryl and alkyl being optionally substituted with one or more groups independently selected from R¹⁵; and

WO 2004/073606 PCT/US2004/002015

-396-

 R^{15} is: hydrogen, nitro, cyano, hydroxyl, halo. haloalkyl, haloalkyloxy, aryloxy, oxo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, $(CH_2)_n$ - C_3 - C_6 cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$. SR^8 , $S(O)_pR^8$ or $S(O)_2NR^8R^9$.

- 5 2. The compound Claim 1, wherein X and Y are respectively S and O; S and C; or C and O.
 - 3. The compound of Claim 2, wherein Z is C_1 - C_6 alkyl, aryl or
 - 4. The compound of Claim 3. wherein Z is phenyl, naphthyl, thiophenyl, oxazolyl, isooxazolyl, pyridyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, pyrazolyl, imidazolyl, 1,4 benzodioxan, benzooxazolyl, benzothiazolyl, benzoimidazolyl, or 2,3-dihydrobenzofuranyl.
 - 5. The compound of Claim 4. wherein R^1 is C_3 - C_6 alkyl or $(CH_2)_n$ - C_3 - C_6 cycloalkyl; R^2 and R^3 are each independently C_1 - C_3 alkyl; and r is 1.
- 6. The compound Claim 5. wherein X is positioned para to Y; and R³ is positioned ortho to Y.
 - A compound having a structural Formula II,

$$Z = (CH_2)_m - S = N - [C]_n - (R^3)_r$$

$$Q$$

$$R^{1a}$$

$$R^{1a}$$

$$R^{2a}$$

$$R^{2a}$$

$$R^{3}$$

$$R^{4}$$

$$R^{5}$$

and pharmaceutically acceptable salts, solvates. hydrates or stereoisomers thereof, wherein:

Q is: $-C(O)OR^6$ or R^{6A} :

10

15

25

X is: a bond, C, O, S or S[O]_p:

WO 2004/073606

```
Y is: a bond, S, C or O;
          Ż is:
                             aliphatic group,
                   a)
    5
                   b)
                            aryl,
                            a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least
                   c)
                            one heteroatom selected from N, O or S,
                            bi-aryl, wherein biaryl being defined as aryl substituted with another aryl
                   d)
                            or aryl substituted with heteroaryl,
  10
                           bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted
                   e)
                            with another heteroaryl, or heteroaryl substituted with aryl, and
                  f)
                           heterocyclyl;
                  wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl
                  being optionally substituted with one or more groups independently selected from
  15
                  R<sup>15</sup>:
        m and n' are each independently: 0, 1, 2, 3 or 4;
         n is:
                  0, 1, 2 or 3:
        p is:
                 1 or 2;
 20
        r is:
                 1. 2, 3 or 4:
        R<sup>1</sup> is: aryl,
                 haloalkyl,
                 C<sub>1</sub>-C<sub>6</sub> alkyl,
25
                C<sub>1</sub>-C<sub>6</sub> alkyl-C<sub>1</sub>-C<sub>6</sub> alkoxy,
                 C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
                C2-C6 alkenyl,
                C2-C6 alkynyl,
                (CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
30
                C<sub>1</sub>-C<sub>6</sub> alkoxy or
```

R¹ and R² together being a 5- to 8-membered heterocyclyl ring, and

wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R¹⁵;

R^{1a} and R^{1b} are each independently:

5 hydrogen,

C₁-C₆ alkyl, or

 R^1 and R^{1a} , R^1 and R^{1b} , R^2 and R^{1a} , R^2 and R^{1b} or R^{1a} and R^{1b} together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R^{1a} and R^{1b} is not hydrogen;

10

R² is: hydrogen,

haloalkyl,

C₁-C₆ alkyl,

C₁-C₆ alkyl-C₁-C₆ alkoxy,

 C_1 - C_6 alkyl-aryl,

C2-C6 alkenyl,

C2-C6 alkynyl,

(CH₂)_n·C₃-C₆ cycloalkyl,

C₁-C₆ alkoxy,

20 aryl, or

R¹ and R² together being a 5- to 8-membered heterocyclyl ring, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R¹⁵;

25 R^{2a} is: hydrogen, halo or C₁-C₆ alkyl and wherein R² and R^{2a} together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from R¹⁵;

R³ is: hydrogen,

30 halo,

cyano.

haloalkyl,

 C_1-C_6 alkyl,

 $(CH_2)_n \cdot C_3 \cdot C_6$ cycloalkyl,

(C₁-C₄ alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo,

5 $(C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9$, and

wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R¹⁵;

R⁴ and R⁵ are each independently:

10 hydrogen,

halo,

C₁-C₆ alkyl

C₁-C₆ alkoxy;

aryloxy;

15 $N(R^8)_2$,

SR⁸ or

R⁴ and R⁵ together being a 3- to 8-membered ring:

 R^6 is: hydrogen, C_1 - C_6 alkyl or aminoalkyl;

20

0t

R^{6A} is: carboxamide, C₁-C₃.alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

R⁷ is: hydrogen or C₁-C₆ alkyl;

25 R⁸ and R⁹ are each independently:

hydrogen, C₁-C₆ alkyl, aryl, heteroaryl, or heterocyclyl, and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C₁-C₆ alkyl and C₁-C₆ alkoxy:

10

15

25

 R^{15} is: hydrogen, nitro, cyano, hydroxyl, halo. haloalkyl, haloalkyloxy, aryloxy, oxo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, $(CH_2)_n$ - C_3 - C_6 cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$, SR^8 . $S(O)_pR^8$ or $S(O)_2NR^8R^9$.

- 5 8. The compound Claim 7, wherein X and Y are respectively S and O; S and C; or C and O.
 - 9. The compound of Claim 8, wherein Z is C_1 - C_6 alkyl, aryl or
 - 10. The compound of Claim 9. wherein Z is phenyl, naphthyl, thiophenyl, oxazolyl, isooxazolyl, pyridyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, pyrazolyl, imidazolyl, 1,4 benzodioxan, benzooxazolyl, benzothiazolyl, benzoimidazolyl, or 2,3-dihydrobenzofuranyl.
 - 11. The compound of Claim 10. wherein R^1 is C_3 - C_6 alkyl or $(CH_2)_n \cdot C_3$ - C_6 cycloalkyl: R^2 and R^3 are each independently C_1 - C_3 alkyl; and r is 1.
- 12. The compound Claim 11. wherein X is positioned para to Y; and R³ is positioned ontho to Y.
 - 13. The compound of Claim 7. wherein the compound having a structural Formula III.

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

n is: 1 or 2;

r is: 1, 2, 3, or 4;

-401-

X is: S or C:

Y is: C or O:

5

Z is: aryl or a 5- to 10-membered heteroaryl, wherein aryl and heteroaryl being optionally substituted with one or more groups independently selected from R¹⁵;

 R^1 and R^2 are each independently: C_1 - C_6 alkyl or $(CH_2)_n$ - C_3 - C_6 cycloalkyl; and R^{1a} and R^{1b} , R^3 , R^4 and R^5 are each independently: hydrogen or C_1 - C_6 alkyl.

14. The compound of Claim 13, wherein the compound having a structural Formula IV,

$$(R^{12})_{q}$$

$$O$$

$$R^{1a}$$

$$S$$

$$R^{4}$$

$$R^{5}$$

$$O$$

$$R^{1}$$

$$R^{1b}$$

$$R^{2}$$

$$IV$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is 1, 2, 3, 4, or 5;

15 R⁸ and R⁹ are each independently:

hydrogen, C_1 - C_6 alkyl, aryl, heteroaryl, or heterocyclyl, wherein alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo. C_1 - C_6 alkyl and C_1 - C_6 alkoxy: and:

 $R^{12} \text{ is: hydrogen, nitro, cyano, hydroxyl, halo. haloalkyl, haloalkyloxy. aryl. heteroaryl, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy. $(CH_2)_n$-C_3-C_6 cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$. $NR^8C(O)_pR^9$, $C(O)NR^8R^9$. $C(O)_pR^8$, SR^8, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.}$

PCT/US2004/002015

15. The compound of Claim 14, wherein the compound having a structural Formula V,

$$(R^{12})_1 \xrightarrow{(R^{12})_2} S \xrightarrow{R^3} CO_2H$$

$$V$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein R^1 and R^2 are each independently C_1 - C_4 alky or $(CH_2)_n$ - C_3 - C_6 cycloalkyl; R^3 is C_1 - C_4 alky; $(R^{12})_1$ is halo, haloalkyl, or haloalkyloxy; and $(R^{12})_2$ is F, Cl or Br.

16. The compound of Claim 15, wherein R^1 is methyl, ethyl, propyl, clcylopropyl, cycloproylmethyl, cyclobutyl: R^3 is methyl and $(R^{12})_1$ is OCF₃.

17. A compound having a structural Formula VI,

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

15 X is: a bond. C, O, S or $S[O]_p$:

5

10

Y is: a bond. S, C or O;

Z is: heteroaryl wherein the heteroaryl containing at least one heteroatom selected from
 N. O or S. and wherein heteroaryl being optionally substituted with one or more groups selected from R¹⁵:

n is: 0. 1, 2 or 3;

```
n' is: 0, 1, 2, 3 or 4;
         p is:
                  1 or 2;
                  1, 2, 3 or 4:
         r is:
         R<sup>1</sup> is: hydrogen,
   5
                   haloalkyl,
                    C<sub>1</sub>-C<sub>6</sub> alkyl,
                    C_1-C_6 alkyl-C_1-C_6 alkoxy,
                    C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
 10
                   C<sub>2</sub>-C<sub>6</sub> alkenyl,
                   C<sub>2</sub>-C<sub>6</sub> alkynyl,
                   (CH_2)_n \cdot C_3 \cdot C_6 cycloalkyl,
                   C_1-C_6 alkoxy,
                   aryl, or
                   R1 and R2 together being a 5- to 8-membered heterocyclyl ring, and
15
                   wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally
                   substituted with one or more groups independently selected from R<sup>15</sup>;
        R<sup>1a</sup> and R<sup>1b</sup> are each independently:
20
                  hydrogen,
                   C<sub>1</sub>-C<sub>6</sub> alkyl, or
                  R^1 and R^{1a}, R^1 and R^{1b}, R^2 and R^{1a}, R^2 and R^{1b} or R^{1a} and R^{1b} together being a 3- to
                  6-membered heterocyclyl or carbocyclyl ring where at least one of R<sup>1a</sup> and R<sup>1b</sup> is
                  not hydrogen;
25
        R<sup>2</sup> is: hydrogen,
                  haloalkyl,
                  C<sub>1</sub>-C<sub>6</sub> alkyl,
                  C_1-C_6 alkyl-C_1-C_6 alkoxy.
30
                  C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
                  C2-C6 alkenyl,
                  C<sub>2</sub>-C<sub>6</sub> alkynyl,
```

 $(CH_2)_n \cdot C_3 \cdot C_6$ cycloalkyl,

 C_1 - C_6 alkoxy,

aryl, or

5

10

25

30

·R¹ and R² together being a 5- to 8-membered heterocyclyl ring, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R¹⁵:

R^{2a} is: hydrogen, halo or C₁-C₆ alkyl and wherein R² and R^{2a} together being a 3- to 8-membered ring: and wherein alkyl being optionally substituted with one or more groups independently selected from R¹⁵:

R³ is: hydrogen,

halo,

cyano,

15 haloalkyl,

C₁-C₆ alkyl,

 $(CH_2)_n \cdot C_3 \cdot C_6$ cycloalkyl,

(C₁-C₄ alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo,

20 $(C_1-C_4 \text{ alkyl})-NR^7C(O)_nR^9$, and

wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R¹⁵;

R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl:

R⁷ is: hydrogen or C₁-C₆ alkyl;

R⁸ and R⁹ are each independently:

hydrogen, C₁-C₆ alkyl, aryl, heteroaryl, or heterocyclyl, and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano,

hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, $C_1\text{-}C_6$ alkyl and $C_1\text{-}C_6$ alkoxy; and

R¹⁵ is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C₁-C₆ alkyl, C₁-C₆ alkoxy, N(R⁸)₂, NR⁸S(O)₂R⁹, NR⁸C(O)_pR⁹, C(O)NR⁸R⁹, C(O)_pR⁸, S(O)_pR⁸ or S(O)₂NR⁸R⁹.

18. The compound of Claim17, wherein the compound having a structural Formula VII.

$$(R^{10})_{q} \xrightarrow{5} \xrightarrow{4} \xrightarrow{R^{11}} \xrightarrow{0} \xrightarrow{R^{13}} \xrightarrow{N} \xrightarrow{C} \begin{bmatrix} C \end{bmatrix}_{n} \xrightarrow{R^{18}} \\ YII$$

10

20

5

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is: 1, 2, 3, or 4:

15 T is: O. NR^{1c} or S:

R^{1c} is: hydrogen or C₁-C₆ alkyl;

P¹⁰ and R¹¹ are each independently:

hydrogen, nitro. cyano, hydroxyl, halo. haloalkyl, haloalkyloxy. aryloxy,

C₁-C₆ alkyl or C₁-C₆ alkoxy; and

wherein alkyl, aryloxy, and alkoxy being optionally substituted with one or more groups independently selected from R¹⁵.

19. The compound of Claim 18, wherein the compound having a structural Formula VIII,

$$(R^{10})_{q} \xrightarrow{5} \xrightarrow{4} \xrightarrow{3} \xrightarrow{0} \\ S \xrightarrow{11} - N \xrightarrow{R^{2}} CO_{2}H$$

$$VIII)$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is: 1 or 2;

5 R^1 is: C_3 - C_5 alky or $(CH_2)_n$ - C_3 - C_6 cycloalkyl;

 R^2 and R^3 are each independently: C_1 - C_3 alkyl;

 R^{10} is: halo, haloalkyl or C_1 - C_3 alkyl, and

wherein R¹⁰ being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring: and

10 R^{11} is: hydrogen or C_1 - C_6 alkyl.

20. The compound of Claim 19, wherein R¹⁰ is Cl, F, Br, CH₃ or CF₃ being substituted at a position 5 of benzothiophenyl ring.

21. A compound having a structural Formula 1X,

$$Z \longrightarrow (CH_2)_m \longrightarrow S \longrightarrow [C]_n \longrightarrow R^{1a} \times R^{2a} \times (R^3)_r \times (R^3)_r \times R^{1b} \times R^{2a} \times (R^3)_r \times ($$

and pharmaceutically acceptable salts. solvates, hydrates or stereoisomers thereof, wherein:

E is: O. S or NR¹⁴;

W is:

 $R^4 \ R^5$, hydrogen, $C_1\text{-}C_6$ alkyl, $(CH_2)_n\cdot C_3\text{-}C_6$ cycloalkyl, haloalkyl or acyl:

Q is: $-C(O)OR^6$ or R^{6A} :

5 X is: a bond, C, O, S or S[O]_p:

Y is: a bond, S, C or O:

Z is: a) aliphatic group.

10 b) aryl,

- c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
- d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,
- bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and
 - f) heterocyclyl;

wherein aliphatic group, aryl. heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R¹⁵:

m and n° are each independently: 0, 1, 2, 3 or 4;

n is: 0, 1, 2 or 3;

p is: 1 or 2;

r is: 1. 2, 3 or 4;

25 v is: 1 or 2;

20

R¹ is: hydrogen,

haloalkyl,

C₁-C₆ alkyl,

 C_1 - C_6 alkyl- C_1 - C_6 alkoxy.

-408-

```
C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
C<sub>2</sub>-C<sub>6</sub> alkenyl,
C<sub>2</sub>-C<sub>6</sub> alkynyl,
(CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl,

5 C<sub>1</sub>-C<sub>6</sub> alkoxy,
aryl, or
R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally
```

R^{1a} and R^{1b} are each independently:

hydrogen,

10

15

30

 C_1 - C_6 alkyl, or

R¹ and R^{1a}, R¹ and R^{1b}, R² and R^{1a}, R² and R^{1b} or R^{1a} and R^{1b} together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R^{1a} and R^{1b} is not hydrogen;

substituted with one or more groups independently selected from R¹⁵:

R² is: hydrogen. haloalkyl.

 C_1 - C_6 alkyl.

C₁-C₆ alkyl-C₁-C₆ alkoxy,

C₁-C₆ alkyl-aryl.

C2-C6 alkenyl,

C2-C6 alkynyl,

25 $(CH_2)_n \cdot C_3 \cdot C_6$ cycloalkyl,

C₁-C₆ alkoxy.

aryl, or

R¹ and R² together being a 5- to 8-membered heterocyclyl ring, and wherein alkyl. aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R¹⁵:

R^{2a} is: hydrogen, halo or C₁-C₆ alkyl and wherein R² and R^{2a} together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from R¹⁵;

5 R³ is: hydrogen,

halo,

cyano,

haloalkyl,

 C_1-C_6 alkyl,

10 $(CH_2)_n \cdot C_3 - C_6$ cycloalkyl,

(C₁-C₄ alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo,

 $(C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9$, and

wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R¹⁵;

 R^4 and R^5 are each independently:

hydrogen,

halo,

 C_1 - C_6 alkyl

15

 C_1 - C_6 alkoxy;

aryloxy:

 $N(R^8)_{2}$

SR⁸ or

25 R⁴ and R⁵ together being a 3- to 8-membered ring;

R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl:

R^{6A} is: carboxamide. C₁-C₃ alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

30 R⁷ is: hydrogen or C₁-C₆ alkyl;

⁸ and R⁹ are each independently:

hydrogen, C_1 - C_6 alkyl, aryl, heteroaryl. or heterocyclyl, and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo. C_1 - C_6 alkyl and C_1 - C_6 alkoxy;

R¹⁴ is: hydrogen, aryl, C₁-C₆ alkyl, or C₁-C₆ alkyl-COOR⁶, and wherein aryl and alkyl being optionally substituted with one or more groups independently selected from R¹⁵; and

R¹⁵ is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C₁-C₆ alkyl, C₁-C₆ alkoxy, $(CH_2)_n$ ·C₃-C₆ cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$, SR^8 , $S(O)_pR^8$ or $S(O)_2NR^8R^9$.

15

10

5

22. The compound of Claim 21. wherein the compound having a structural Formula X:

$$(R^{10})_{q} \xrightarrow{\begin{array}{c} 4 \\ 6 \end{array}} \xrightarrow{\begin{array}{c} 7 \\ 7 \end{array}} \xrightarrow{\begin{array}{c} 13 \\ 10 \\ 7 \end{array}} \xrightarrow{\begin{array}{c} R^{1a} \\ 10 \\ 7 \end{array}} \xrightarrow{\begin{array}{c} R^{1a} \\ 10 \\ 10 \end{array}} \xrightarrow{\begin{array}{c} R^{1a} \\ 10 \\ 10 \end{array}} \xrightarrow{\begin{array}{c} 13 \\ 10 \end{array}} \xrightarrow{\begin{array}{c} 13$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof,

20 wherein:

n and q are each independently: 1, 2. 3 or 4:

T is: O. NR 1c or S;

X is: C, O or S;

 R^1 is: hydrogen, C_1 - C_6 alkyl or $(CH_2)_n$ - C_3 - C_6 cycloalkyl;

R^{1a}, R^{1b}, R^{1c} and R² are each independently: hydrogen or C₁-C₆ alkyl: and R¹⁰ and R¹¹ are each independently:

hydrogen. nitro, cyano, hydroxyl, halo. haloalkyl, haloalkyloxy. aryloxy,

 C_1 - C_6 alkyl or C_1 - C_6 alkoxy; and wherein alkyl, alkoxy and aryloxy being optionally substituted with one or more groups selected from R^{15} .

23. The compound of Claim 22. wherein the compound having a

5 structural Formula X1:

$$(R^{10})_{q} \xrightarrow{\begin{array}{c} 5 \\ 6 \end{array} \begin{array}{c} 4 \\ 5 \\ 7 \end{array} \begin{array}{c} 3 \\ 5 \\ 0 \end{array} \begin{array}{c} 11 \\ 8 \\ 0 \end{array} \begin{array}{c} 11 \\ R^{1} \end{array}$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is 1 or 2;

10 E is O, S or NR¹⁴;

 R^1 , R^2 and R^{11} are each independently: C_1 - C_4 alkyl:

R¹⁰ is: Cl, F, Br, CH₃ or CF₃, and wherein R¹⁰ being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring; and

R¹⁴ is: hydrogen, C₁-C₆ alkyl or aryl.

15

121:

24. A compound selected from the group consisting of No. 1-120 and

No.	Structure	Name
	S S N S OH	3-(4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
2	CI S S N S	3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-

No.	Structure	Name
		2-methyl-phenyl)-
1		propionic acid
3	CI	(4-{2-[(5-Chloro-3-
1		methyl-benzofuran-2-
	OH OH	sulfonyl)-propyl-
)		amino]-1-methyl-
}		ethoxy}-2-methyl-
		phenoxy)-acetic acid
4	CI	(4-{2-[(5-Chloro-3-
}		methyl-benzofuran-2-
	OH ON	sulfonyl)-propyl-
		amino]-1-methyl-
Ì		ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
		acid
5	CI	3-(4-{2-[(5-Chloro-3-
		methyl-
1	OH C	benzo[b]thiophene-2-
Į	show how	sulfonyl)-propyl-
		amino]-1-methyl-
		ethylsulfanyl}-2-
		methyl-phenyl)-
		propionic acid
6	CI	(4-{2-[(5-Chloro-3-
		ethyl-
	OH OH	benzo[b]thiophene-2-
	's 's N s '	sulfonyl)-propyl-
ļ	s sin s	amino]-1-methyl-
İ		ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
		acid
7		4-{2-[(6-Chloro-3-
} }	CI-()-(OH)	methyl-
}		benzo[b]thiophene-2-
} }	5 .s. ~ 's' ~	sulfonyl)-propyl-
	o u	amino]-ethylsulfanyl}-
i I		2-methyl-phenoxy)-
8		acetic acid
8		4-{2-[(7-Chloro-3-
} {	OH I	methyl-
} }		benzo[b]thiophene-2-
		sulfonyl)-propyl-
	- 0	amino]-ethylsulfanyl}-
1		2-methyl-phenoxy)-
L		acetic acid

No.	Structure	Name
9	,CI	(4-{2-[(4-Chloro-3-
Ţ		methyl-
	OH CONTRACTOR	benzo[b]thiophene-2-
	she in the second secon	sulfonyl)-propyl-
	0,5	amino]-ethylsulfanyl}-
l		2-methyl-phenoxy)-
		acetic acid
10	CI F F D	(4-{2-[(5-Chloro-3-
		trifluoromethyl-
1	OH	benzo[b]thiophene-2-
	S S S N S S	sulfonyl)-propyl-
	0,0	amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
11	Ch CF ₃ O	(4-{2-[(5-Chloro-3-
1	S-N.	trifluoromethyl-
		benzo[b]thiophene-2-
}		sulfonyl)-propyl-
	0	amino]-1-methyl-
		ethoxy}-2-methyl-
12		phenoxy)-acetic acid
12	J ~ n l	2-[4-(3-{[5-(4'-Fluoro-
1	F-OH	biphenyl-4-yl)-
}	's sisin	thiophene-2-sulfonyl]-
1		propyl-amino}-propyl)-
}		phenoxy]-2-methyl-
13	, , , , , , , , , , , , , , , , , , , ,	propionic acid
, ,	0 <	2-(4-{2-[(5-Chloro-3-
	s S S N	methyl-
		benzo[b]thiophene-2-
		sulfonyl)-propyl-
	CI OH	amino]-ethyl}-
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	phenoxy)-2-methyl- propionic acid
14	/	2-(4-{3-[(3,5-Dimethyl-
		benzo[b]thiophene-2-
		sulfonyl)-propyl-
l	O O OH	amino]-propyl}-
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	phenoxy)-2-methyl-
		propionic acid
15	F / 0	2-(4-{3-[(5-Fluoro-3-
- 1		methyl-
[benzo[b]thiophene-2-
l	OH OH	sulfonyl)-propyl-
Į	`	amino]-propyl}-
		phenoxy)-2-methyl-

No	. Structure	Nome
		Name
16	CI	propionic acid
		2-(4-{3-[(5-Chloro-3-
		methyl-
	s	benzo[b]thiophene-2-
	O OH	sulfonyl)-(2,2,2-
	F / F	umuoro-emyr)-ammo -
ŀ		propyl}-phenoxy)-2-
17		methyl-propionic acid
1	9 00	2-(4-{2-[(3-Ethy]-
	S N S	benzo[b]thiophene-2-
1	s ii	sulfonyl)-propyl-
-	ОН	amino]-ethoxy}-3-
		propyl-phenoxy)-2-
18		methyl-propionic acid
1 10	Cl	2-[4-(1-{[(5-Chloro-3-
1		methyl-
		benzo[b]thiophene-2-
	HO, CH	sulfonyl)-propyl-
	S S N O O O O O O O O O O O O O O O O O	amino]-methyl}-
	O N Y	propoxy)-2-methyl-
		phenoxy]-2-methyl-
1		propionic acid
19	CI	
		3-[4-(1-{[(5-Chloro-3-
		methyl-
	OH	benzo[b]thiophene-2-
		sulfonyl)-propyl-
	S S N	amino]-methyl}-
	J	propoxy)-2-methyl-
		phenyl]-propionic acid
- 20		
20	F,	[4-(1-{[(5-Fluoro-3-
		methyl-
		benzo[b]thiophene-2-
	OH I	sulfonyl)-propyl-
	S O S O OH	amino]-methyl}-
	0,2,N, \3	propylsulfanyl)-2-
	/ /	methyl-phenoxy]-acetic
	\	acid
2]		
-		[4-(1-{[(5-Chloro-3-
	CI	methyl-
		benzo[b]thiophene-2-
ŀ	~ s o N > s	sulfonyl)-propyl-
		amino]-methyl}-
		propylsulfanyl)-2-
	,	methyl-phenoxy]-acetic

No.	Structure	Name
110.	Strate Control of the	acid
22	CI S S N S	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-aceticacid
23	O-N=S-CH ₃ OH OCH ₃	(2-Methyl-4-{2-[(6-phenoxy-pyridine-3-sulfonyl)-propyl-amino]-ethylsulfanyl} phenoxy)-acetic acid
24	CH ₃ CH ₂ OH	(2-Methyl-4-{2-[(5-methyl-1-phenyl-1H-pyrazole-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
25	CH ₃	(2-Methyl-4-{2-{(4-oxazol-5-yl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
26	CH ₃	(2-Methyl-4-{2-[propyl-(4-pyrazol-1-yl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
27	CH ₃ CH ₅	(2-Methyl-4-{2-[(2-naphthalen-1-yl-ethanesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid

No.	Structure	Name
28	F F O CH ₃ O OH	(2-Methyl-4-{2-[propyl- (4- trifluoromethylphenylm ethanesulfonyl)-amino]- ethylsulfanyl}-
29	CH ₃ CH ₃ O CH ₃ O O O O O O O O O O O O O	phenoxy)-acetic acid (4-{2-[(Biphenyl-3-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
30	CH ₃	(4-{2-[(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
31	H ₃ C S N S CH ₃ OH	[2-Methyl-4-(2-{[5-(2-methylsulfanyl-pyrimidin-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid
32	F H ₅ C CH ₅	[2-Methyl-4-(2-{[5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-sulfonyl]-propylamino}-ethylsulfanyl)-phenoxy]-acetic acid
33	F F S O CH ₃ CH ₃ O O O O O	[2-Methyl-4-(2-{[5-(1-methyl-3-trifluoromethyl-1]pyrazol-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid
34	F CH ₃ Chiral CH ₅ Ch ₅ CH ₅ CH ₅ OH	(R)-(2-Methyl-4-{1- methyl-2-[(3-methyl-5- trifluoromethyl- benzo[b]thiophene-2- sulfonyl)-propyl- amino]-ethylsulfanyl}-

No.	Structure	Name
		phenoxy)-acetic acid
35	CH ₃ chiral	(R)-3-(4-{2-[(6-Chloro-
	F CH ₃	5-fluoro-3-methyl-
1		benzo[b]thiophene-2-
	CI S' Ö CH ₃	sulfonyl)-propyl-
-		amino]-1-methyl-
[ĊН ₃ ОН	ethylsulfanyl}-2-
ļ		methyl-phenyl)-
		propionic acid
36	CH ₃ chiral	(R)-(4-{2-[(6-Chloro-5-
ĺ	CI S CH ₃	fluoro-3-methyl-
	CI S O CH ₃	benzo[b]thiophene-2-
}	CI CH ₃ CH ₃	sulfonyl)-propyl-
}	CH ₃ OH	amino]-1-methyl-
1		ethylsulfanyl}-2-
1		methyl-phenoxy)-acetic
37		acid
3/	0 0	(4-{2-[(4-Bromo-
	S CH ₃	benzenesulfonyl)-
		propyl-amino]-
	Br	ethylsulfanyl}-2-
	сн₃ о́н	methyl-phenoxy)-acetic
38	0	acid
	CI S S CH ₃	(4-{2-[(3,4-Dichloro-benzenesulfonyl)-
Ì		propyl-amino]-
İ		ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
	CH ₃ ÖH	acid
39	0	(4-{2-[(4-]sopropy]-
	S CH ₃	benzenesulfonyl)-
		propyl-amino]-
	H ₃ C O	ethylsulfanyl}-2-
	CH ₃ CH ₃ OH	methyl-phenoxy)-acetic
	-	acid
40	O S CH,	(2-Methyl-4-{2-[(4-
	S S CH.	pentyl-
!		benzenesulfonyl)-
}	H,C	propyl-amino]-
	сн _s он	ethylsulfanyl}-
		phenoxy)-acetic acid
		phenoxy)-acetic acid

No.	Structure	132
41		Name (4.12.1/2.Ch)
}	CI O II S CH ₃	(4-{2-[(2-Chloro-4-
ĺ	F N V V V V V V V V V V V V V V V V V V	trifluoromethyl-
Ì	F O O	benzenesulfonyl)- propyl-aminol-
	F CH ₃	ethylsulfanyl}-2-
}	F CH ₃ ÓH	methyl-phenoxy)-acetic
		acid
42	F 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	(2-Methyl-4-{2-[propyl-
l	S CH ₃	(3-trifluoromethyl-
		benzenesulfonyl)-
1		amino]-ethylsulfanyl}-
1	CH ₃	phenoxy)-acetic acid
43	CH O	(4-{2-[(4-Bromo-2-
	S CH ₃	methyl-
j		benzenesulfonyl)-
1	Br	propyl-amino]-
	CH ₃ OH	ethylsulfanyl}-2-
	CH₃ OH	methyl-phenoxy)-acetic
44		acid
44	0 0	(4-{2-[(3,4-Dibromo-
ĺ	Br S CH ₃	benzenesulfonyl)-
		propyl-amino]-
	Br	ethylsulfanyl}-2-
	ĊH ₃ о́н	methyl-phenoxy)-acetic
45	0,1	acid (2-Methyl-4-{2-[propy]-
	S CH ₃	(4-propy)-
1		benzenesulfonyl)-
Ì	H ₃ C 0	amino]-ethylsulfanyl}-
	ĊH ₃ ОН	phenoxy)-acetic acid
46	CI O S CH	(4-{2-[(2,4-Dichloro-
l	S CH ₃	benzenesulfonyl)-
1		propyl-amino]-
l	CI O	ethylsulfanyl}-2-
{	Ċн _з Он	methyl-phenoxy)-acetic
47		acid
	O O II	(4-{2-[(4-]odo-
- 1		benzenesulfonyl)- propyl-aminol-
		ethylsulfanyl}-2-
	CH	methyl-phenoxy)-acetic
	CH ₃ ÓH	acid

No.	Structure	
48		Name
	CI S CH ₃	(4-{2-[(3-Chloro-4-
	1	methyl-
	H ₃ C	benzenesulfonyl)-
		propyl-amino]-
	CH₃ ÓH	ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
49	F O	acid
	F O S CH	(4-{2-[(4-Bromo-2,5-
	S N CH3	difluoro-
		benzenesulfonyl)-
	Br	propyl-amino]-
	F CH₃ OH	ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
50	O chiral	acid
	0.511	(2-Methyl-4-{1-methyl-
	S CH ₃	2-[propyl-(4-
	F F CH ₃	trifluoromethyl-
		benzenesulfonyl)-
ŀ	F CH ₃	amino]-ethylsulfanyl}-
51	chinal	phenoxy)-acetic acid
	O chiral	(4-{2-[(3,4-Dichloro-
	CI S CH ₃	benzenesulfonyl)-
		propyl-amino]-1-
}	CI CH ₃	methyl-ethylsulfanyl}-
		2-methyl-phenoxy)-
52		acetic acid
32	F F 0	(2-Methyl-4-{2-[propyl-
1	F F S N S CH ₃	(2'-trifluoromethyl-
		biphenyl-4-sulfonyl)-
		amino]-ethylsulfanyl}-
	ĊH ₃	phenoxy)-acetic acid
53	0.11	
	F E CH,	(2-Methyl-4-{2-[propyl- (3'-trifluoromethyl-
		biphenyl-4-sulfonyl)-
		amino]-ethylsulfanyl}-
	сн, он	phenoxy)-acetic acid
54	O S CH.	(2-Methyl-4-{2-[propy]-
	S CH,	(4'-trifluoromethyl-
}		biphenyl-4-sulfonyl)-
	- F	amino]-ethylsulfanyl}-
	CH ₂ OH	phenoxy)-acetic acid
	<u> </u>	promotify decide acid

No.	Structure	Name
55	0	(4-{2-[(2'-Fluoro-
ļ	E S CH ₃	biphenyl-4-sulfonyl)-
		propyl-amino]-
		ethylsulfanyl}-2-
	ĊН ₃ О́Н	methyl-phenoxy)-acetic
		acid
56	0 0 5 0 5	(4-{2-[(4'-Fluoro-
	S N CH3	biphenyl-4-sulfonyl)-
ļ		propyl-amino]-
	CH, OH	ethylsulfanyl}-2-
	F CH ₃ OH	methyl-phenoxy)-acetic
57	0	acid
]],	OSII SS N S CH3	(2-Methyl-4-{2-[propyl-
]		(4'-trifluoromethoxy- biphenyl-4-sulfonyl)-
		amino]-ethylsulfanyl}-
1	F O CH ₃ OH	phenoxy)-acetic acid
58	0 0	(4-{2-[(3',4'-Dichloro-
ļ	S CH ₃	biphenyl-4-sulfonyl)-
		propyl-amino]-
į		ethylsulfanyl}-2-
}	CI CH ₃ OH	methyl-phenoxy)-acetic
		acid
59	0 1 5 6 6	(4-{2-[(3'-Fluoro-
	S N S CH3	biphenyl-4-sulfonyl)-
	F	propyl-amino]-
		ethylsulfanyl}-2-
	ĊH₃ ÓH	methyl-phenoxy)-acetic
60		acid
60	O II S CH ₃	(4-{2-[(2'-Chloro-
	CI SN SCH3	biphenyl-4-sulfonyl)-
		propyl-amino]-
	CH ₃ OH	ethylsulfanyl}-2-
	On	methyl-phenoxy)-acetic acid
61	0,1	(4-{2-[(4'-Methoxy-
	S CH ₃	biphenyl-4-sulfonyl)-
}		propyl-amino]-
		ethylsulfanyl}-2-
ŀ	CI CH ₃ ÓH	methyl-phenoxy)-acetic
		acid
62	O S CH.	(4-{2-[(4'-Methoxy-
	S N S CH,	biphenyl-4-sulfonyl)-
!		propyl-amino]-
1	H,C OH	ethylsulfanyl\-2-
		methyl-phenoxy)-acetic

No.	Structure	15.
3.0.	Structure	Name
63	0	acid
03		(4-{2-[(3'-Chloro-4'-
4	S N S CH ₃	fluoro-biphenyl-4-
	CI	sulfonyl)-propyl-
		amino]-ethylsulfanyl}-
	F CH₃ ÖH	2-methyl-phenoxy)-
64	F	acetic acid
04	F ON O	(4-{2-[(4-Chloro-3-
ł	F S N S CH ₃	trifluoromethyl-
		benzenesulfonyl)-
1	CI	propyl-amino]-
[CH ₃	ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
		acid
65	O chiral	(2-Methyl-4-{1-methyl-
1	S CH ₃	2-[propyl-(4-
1		trifluoromethoxy-
	F CH ₃	benzenesulfonyl)-
1	F CH ₃ OH	amino]-ethylsulfanyl}-
		phenoxy)-acetic acid
66	O chiral	(2-Methyl-4-{1-methyl-
	S CH ₃	2-[propyl-(4-propyl-
	H.C CH ₃	benzenesulfonyl)-
	H ₃ C CH ₃	amino]-ethylsulfanyl}-
	ĊH₃ ÖH	phenoxy)-acetic acid
67	F o Chiral	(4-{2-[(4-Chloro-3-
ļ .	F O Chiral	trifluoromethyl-
	F S N CH ₃	benzenesulfonyl)-
	CH ₃	propyl-amino]-1-
	CI CI CI CI CI CI CI CI CI CI CI CI CI C	methyl-ethylsulfanyl}-
	CH₃ ÓH	2-methyl-phenoxy)-
		acetic acid
68	C chiral	(4-{2-[(3-Chloro-4-
	0.√ĬĬ	trifluoromethyl-
[CH ₃	benzenesulfonyl)-
	F CH ₃	propyl-amino]-1-
		methyl-ethylsulfanyl}-
	Ė ĊH₃ ÔH	2-methyl-phenoxy)-
		acetic acid
69	O O CH.	(4-{2-[(4-Butyl-
ļ	S CH _s	benzenesulfonyl)-
	H,C, \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	propyl-amino]-
		ethylsulfanyl}-2-
	ċн, о́н	methyl-phenoxy)-acetic
		acid

No.	Structure	Name
70	O CH.	(4-{2-[(4-]sobuty]-
, v		benzenesulfonyl)-
	CH ₃	propyl-amino]-
	H ₃ C O	ethylsulfanyl}-2-
'	° сн _з он	methyl-phenoxy)-acetic
		acid
71	Cl O chiral	(4-{2-[(2-Chloro-4-
,,	CI O CHIPAI	trifluoromethyl-
		benzenesulfonyl)-
	F, CH ₃	propyl-amino]-1-
	L CH OH	methyl-ethylsulfanyl}-
	F CH ₃	2-methyl-phenoxy)-
		acetic acid
72	O chiral	(4-{2-[(4-Bromo-3-
	CI S CH ₃	chloro-
1	CH ₃	benzenesulfonyl)-
1	Br CH ₃	propyl-amino]-1-
1	CH ₃	methyl-ethylsulfanyl}-
l	Cri ₃	2-methyl-phenoxy)- acetic acid
		(4-{2-[(4-Butyl-3-
73	chiral	(4-{2-[(4-Butyl-3-
1	CI S CH ₃	benzenesulfonyl)-
1	H,C, CH,	propyl-amino]-1-
1		methyl-ethylsulfanyl}-
1	CH ₃ OH	2-methyl-phenoxy)-
		acetic acid
74	O chiral	(4-{2-[(3-Chloro-4-
74	0-11	isobutyl-
	CH3 Y Y N Y Y Y	benzenesulfonyl)-
	H ₃ C CH ₃ CH ₃	propyl-amino]-1-
	CH ₃	methyl-ethylsulfanyl}-
}	- 3	2-methyl-phenoxy)-
1		acetic acid
75	O chiral	(4-{2-[(4-Bromo-
1	O chiral	benzenesulfonyl)-
1		propyl-amino]-1-
	CH _s	1110(11)1 0(11)1041114111
	Br CH OH	2-methyl-phenoxy)-
	Ol 18	acetic acid
76	O chiral	(4-{2-[(4-Butyl-
1	S CH ₃	benzenesulfonyl)-
1	H ₃ C CH ₃	propyl-amino]-1- methyl-ethylsulfanyl}-
		2-methyl-phenoxy)-
	CH, OH	acetic acid
		aceije acid

No.	Structure	131-
77	chirol	Name
	0~11	(4-{2-[(2-Chloro-4'-
	S CH ₃	fluoro-biphenyl-4-
	CH ₃	sulfonyl)-propyl-
		aminoj-i-methyl-
	CH ₃ OH	ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
78	O chiral	acid
	0,1	(4-{2-[(3-Chloro-4-
}	CI N S N CH3	propyl-
	H.C. CH ₃	benzenesulfonyl)-
	130	propyl-amino]-1-
	CH ₃ ÓH	methyl-ethylsulfanyl}-
		2-methyl-phenoxy)-
79	,CH ₃	acetic acid
	("13	(4-{2-[(5-Chloro-3-
	CH ₃	methyl-
1	CI OH	benzo[b]thiophene-2-
		sulfonyl)-propyl-
		amino]-ethylsulfanyl}-
	Сн³	2-propyl-phenoxy)-
80	CI CH ₃ O S OH	acetic acid
		(4-{2-[(5-Chloro-3-
- 1	SOH	methyl-
]		benzo[b]thiophene-2-
]		sulfonyl)-propyl-
	ċн₃	amino]-ethylsulfanyl}-
81	F _F	phenoxy)-acetic acid
}	Ϋ́F	(4-{2-[(5-Chloro-3-
1	CH _s s o	methyl-
1		benzo[b]thiophene-2-
- 1	S N OH	sulfonyl)-propyl-
1		amino]-ethylsulfanyl}-
	CH ₃	2-trifluoromethyl-
82	F.F.F	phenoxy)-acetic acid
	ÇH₃ ÇH₃ Q	[2-Methyl-4-(1-
1	○〜 ノ、CH。人、O. ↓ l	{[propy]-(4-
- 1	I I I I OH	trifluoromethoxy- benzenesulfonyl)-
i	S.S. S.	
1	0 0	amino]-methyl}-
		propylsulfanyl)-
		phenoxy]-acetic acid

Structure	Name
,CH ₃	(4-{2-[(5-Chloro-3-
	methyl-
CH ₃ S—)—O O	benzo[b]thiophene-2-
CH OH	sulfonyl)-propyl-
s ii ii	amino]-1-methyl-
\ \ \ \	ethylsulfanyl}-2-
CH₃	methyl-phenoxy)-acetic
	acid
CH ₃	(4-{2-[(5-Chloro-3-
	methyl-
CH ₃ S-\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	benzo[b]thiophene-2-
	sulfonyl)-propyl-
S S CL3	amino]-1-methyl-
) ~ 5 0 /	ethylsulfanyl}-2-
CH ₃	methyl-phenoxy)-acetic
	acid
F CH CH	(2-Methyl-4-{2-[(3-
	methyl-5-
r i	trifluoromethyl-
s ö	benzo[b]thiophene-2-
3————	sulfonyl)-propyl-
он	amino]-ethylsulfanyl}-
	phenoxy)-acetic acid
CH ₃	(2-Methyl-4-{2-[propyl-
F. O	(4-trifluoromethyl-
F-Y-S-N CH ₃	benzenesulfonyl)-
	amino]-ethylsulfanyl}-
	phenoxy)-acetic acid
'он	
CH ₂	(4-{2-[(4-Ethyl-
	benzenesulfonyl)-
1 1 0	propyl-amino]-
S'N S	ethylsulfanyl}-2-
O' N T T CIT'3	methyl-phenoxy)-acetic
	acid
CH ₃	
7	
ÓН	
	CI CH ₃ O O O O O O O O O O O O O O O O O O O

No.	Structure	Name
88	OH CH ₃	(2-Methyl-4-{2-[(2-methyl-4-trifluoromethoxy-
	S—N. O.O. CH3	benzenesulfonyl)- propyl-amino]- ethylsulfanyl}- phenoxy)-acetic acid
89	F O SII3 CH3 CH3 OH CH3	(2-Methyl-4-{2-[propyl- (4-trifluoromethoxy- benzenesulfonyl)- amino]-ethylsulfanyl}- phenoxy)-acetic acid
90	CH ₃ CH ₃ S-N OH CH ₃	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
91	CI CH ₃ OH OH OH	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-(3-methyl-butyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
92	CI CH ₃ O O O O O O O O O O O O O O O O O O O	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-cyclopropyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
93	CH ₃ O S S O O O O O O O O O O O O O O	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-cyclobutyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

No.	Structure	
94	CH ₃	Name
		(4-{2-[(5-Chloro-3-
1	CH ₃ S-()-0 0	methyl-
		benzo[b]thiophene-2-sulfonyl)-
	OH OH	cyclopropylmethyl-
		amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
95	CH ₃	(4-{2-[(5-Chloro-3-
	CH ₃ S-(-)-0 0	methyl-
1	C C C C C C C C C C C C C C C C C C C	benzo[b]thiophene-2-
	S OH	sulfonyl)-pentyl-amino]-
1		ethylsulfanyl}-2-
{	/	methyl-phenoxy)-acetic
	CH ₃	acju
96	,CH ₃	(4-{2-[Butyl-(5-chloro-
		3-methyl-
	CI S S	benzo[b]thiophene-2-
1	CI S-N OH	sulfonyl)-amino]-
		ethylsulfanyl}-2-
)	methyl-phenoxy)-acetic
	H ₃ C	acid
97	CH ₃	(4-{2-[(Bipheny]-4-
	СН ₃	sulfonyl)-propyl-
1		amino]-ethylsulfanyl}-
1	s-()-0, ,0	2-methyl-phenoxy)-
1	ОН	acetic acid
98	,CH ₃	(4-{2-[(5-Chloro-3-
		methyl-
	CI S	benzo[b]thiophene-2-
	S-N OH	sulfonyl)-propyl-
	~ ° ° /	amino]-ethoxy}-2-
	СН³	methyl-phenylsulfanyl)-
99		acetic acid
79	CH ₃	(4-{3-[(5-Ch]oro-3-
1	CI CH ₃ O OH	methyl-
j	S-N OH	benzo[b]thiophene-2-
	∞ s' ö ⟩	sulfonyl)-propyl- amino]-propyl}-2-
{	CH _s	methyl-phenoxy)-acetic
		acid

No.	Structure	Name
100	,CH _s	(4-{2-[(5-Chloro-3-
		methyl-
		benzo[b]thiophene-2-
	│	sulfonyl)-propyl-
}	CH ₃ O CH ₃ O OH	amino]-1-methyl-
	1	ethoxy}-2-methyl-
ļ	CH ₃	phenoxy)-acetic acid
101	,CH₃	3-(4-{2-[(5-Chloro-3-
1	CH O	methyl-
	CI CI	benzo[b]thiophene-2-
	CH ₃ O CH ₃ O OH	sulfonyl)-propyl-
	s 5 >	amino]-1-methyl-
	(ethoxy}-2-methyl-
	. CH³	phenyl)-propionic acid
102	CH3	2-(4-{2-[(5-Chloro-3-
1	CH3 O- O O	methyl-
	CI S S N CH ₃ H ₃ C OH	benzo[b]thiophene-2-
	CI H ₃ C OH	sulfonyl)-propyl-
	s ö	amino]-1-methyl-
1	CH ₃	ethoxy}-2-methyl-
	Sing.	phenoxy)-2-methyl-
103	,O-СН ₄	propionic acid
100		3-(4-{2-[(5-Chloro-3-
)]	CI CH ₃ O CH	methyl-
		benzo[b]thiophene-2- sulfonyl)-propyl-
) !	S CH ₃ OH	amino]-1-methyl-
	<u> </u>	ethoxy}-2-methoxy-
	,CH³	phenyl)-propionic acid
104	,CH ₂	(4-{2-[(5-Fluoro-3-
	/ ==	methyl-
	F CH ₃ S O	benzo[b]thiophene-2-
	I II ">→S-N CH OH	sulfonyl)-propyl-
	s' i s'	amino]-1-methyl-
	(CH	ethylsulfanyl}-2-
	CH ₃	methyl-phenoxy)-acetic
105		acid
105	CH,	3-(4-{2-[(5-Fluoro-3-
1	F CH ₃ O CH ₃ O OH	methyl-
1	F ~ ° ° ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	benzo[b]thiophene-2-
{	S SH CH3 OH	sulfonyl)-propyl-
1	~ ~ 0 /	amino]-1-methyl-
	CH*	ethoxy}-2-methyl-
	•	phenyl)-propionic acid

No.	Structure	Name
106	,CH ₃	(4-{2-[(5-Fluoro-3-
{		methyl-
	F. CH ₃ O O	benzo[b]thiophene-2-
	F CH ₃ OH	sulfonyl)-propyl-
	s' ö	amino]-1-methyl-
1		ethoxy}-2-methyl-
	,CH³	phenoxy)-acetic acid
107	,Cl	(2-Chloro-4-{2-{(5-
}		chloro-3-methyl-
	Ch S CH ₃ O S O	benzo[b]thiophene-2-
1	CI S S OH	sulfonyl)-propyl-
-	s' ö	amino]-ethylsulfanyl}-
1	(phenoxy)-acetic acid
L	CH ₃	
108	CH ₃ CH ₃	(4-{2-[(5-Ch]oro-3-
		methyl-
	S S CH ₃	benzo[b]thiophene-2-
}	s-()-o o	sulfonyl)-propyl-
}		amino]-ethylsulfanyl}-
1	он	2-ethyl-phenoxy)-acetic
100	01)	acid
109	OH OH	(2-Methyl-4-{2-
	O=_O, CH ₃	[(naphthalene-2-
		sulfonyl)-propyl-
	CH₃	amino]-ethylsulfanyl}-
	's T	phenoxy)-acetic acid
}	<u>√</u> N0	
} }	0,5	1
1 1	(<u>)</u>	
110	A	(4-{2-[(5-Fluoro-3-
] }	H ₃ C Q S F	methyl-
	N-S	benzo[b]thiophene-2-
	Č Ö ĆH ₃	sulfonyl)-propyl-
	H ₃ C	amino]-ethylsulfanyl}-
	HO TS	2-methyl-phenoxy)-
	<i>II</i> 'o'	acetic acid
111	0	
,,,	CH ₃ CH ₃	[3-Chloro-4-(1-
	F, A P I	{[propyl-(4-
	F-0	trifluoromethoxy-
	F Ö CI O	benzenesulfonyl)-
1	Si O	amino]-methyl}-
		propylsulfanyl)-phenyl]-

No.	Structure	None
·		Name
112	CH ₃ Chiral	acetic acid
	CI S S	(R)-(3-Chloro-4-{2-[(5-
	CI S OH CHÇI O OH	chloro-3-methyl-
1	S OH CHCI O	benzo[b]thiophene-2-
		sulfonyl)-propyl-
}	CH ₃	amino]-1-methyl-
		ethylsulfanyl}-phenyl)-
113		acetic acid
113	CH S	(3-Chloro-4-{2-[(5-
	CI CH S	chloro-3-methyl-
	S-N CI HO	benzo[b]thiophene-2-
	s' ö	sulfonyl)-propyl-
	CH₃	amino]-ethylsulfanyl}-
111	5113	phenyl)-acetic acid
114		[4-(1-{[(5-Fluoro-3-
	ÇH₃ Q	methyl-
	$\bigcup_{i\in\mathcal{N}}CH_{i}$ $\bigcup_{i\in\mathcal{N}}CH_{i}$	benzo[b]thiophene-2-
	S-CO I TO OH	sulfonyl)-propyl-
	S S N O O O O O O O O O O O O O O O O O	amino]-methyl}-
ļ	ا رُ ٥	propoxy)-2-methyl-
	CH³C	phenoxy]-acetic acid
		, , , , , , , , , , , , , , , , , , , ,
115	F	3-[4-(1-{[(5-Fluoro-3-
	ÇH ₃ Q	methyl-
ļ	CH ₃	benzo[b]thiophene-2-
ļ	SON	sulfonyl)-propyl-
	o's'N	amino]-methyl}-
	0)]	propoxy)-2-methyl-
Į.	CH³C CH³C	phenyl]-propionic acid
-,		
116	CI	3-(4-{2-[(5-Chloro-3-
	CH. CH ₃ O	methyl-
ļ	CH ₃ au	benzo[b]thiophene-2-
	S O CH ₃	sulfonyl)-propyl-
ļ	,s. _N o	amino]-butoxy}-2-
· 1		methyl-phenyl)-
- 1	<u> </u>	propionic acid
	CH ₂	
117	Cl	[4-(1-{[(5-Chloro-3-
	CH ₃ O	methyl-
	\\ \rightarrow CH.	benzo[b]thiophene-2-
1	S OH	sulfonyl)-propyl-
1	SNO	amino]-methyl}-
1	S O OH	propoxy)-2-methyl-
1		phenoxy]-acetic acid
1	CH ₃ °	,

No.	Structure	
118	CI	Name
	CH ₃ CH ₃ O CH ₃ O O CH ₃ O O O O O O O O O O O O O O O O O O O	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methoxy-phenoxy]-acetic acid
119	CH ₃ CH ₃ O OH	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-phenethyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
120	CH ₃ OH OH	(4-{2-[Benzyl-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
121	CH ₃ CH ₃ O O OH SO S N S CH ₃ C	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid

25. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound of Claims 1-24 or pharmaceutically acceptable salts, solvates or hydrates thereof.

5

10

26. A pharmaceutical composition comprising (1) a compound of Claim 1-24, or a pharmaceutically acceptable salt. solvate, hydrate or stereoisomer thereof; (2) a second therapeutic agent selected from the group consisting of insulin sensitizers, sulfonylureas, biguanides, thiazolidinediones, α-glucosidase inhibitors, insulin secretogogues, insulin, antihyperlipidemic agents, plasma HDL-raising agents,

20

HMG-CoA reductase inhibitors, statins, acryl CoA:cholestrol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin; and (3) a pharmaceutically acceptable carrier.

- 5 27. A method of modulating a peroxisome proliferator activated receptor (PPAR), comprising the step of contacting the receptor with at least one compound of Claims 1-24, or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- The method of Claim 27, wherein the PPAR is a gamma receptor.
 - 29. The method of Claim 27, wherein the PPAR is a delta-receptor.
- 30. The method of Claim 27, wherein the PPAR is a gamma and delta-15 receptor.
 - 31. A method for treating or preventing a PPAR-gamma mediated disease or condition in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24.
 - 32. A method for treating or preventing a PPAR-delta mediated disease or condition in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24.
- 25 33. A method for treating or preventing a PPAR-gamma and delta mediated disease or condition in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24.
- 34. A method for lowering blood-glucose in a mammal comprising the step of administering an effective amount of at least one compound of Claims 1-24.

WO 2004/073606 PCT/US2004/002015

-432-

35. A method of treating or preventing disease or condition in a mammal selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of at least one compound of Claims 1-24.

5

15

20

25

- 36. A method of treating or preventing diabetes mellitus in a mammal comprising the step of administering to a mammal a therapeutically effective amount of at least one compound of Claims 1-24.
 - 37. A method of treating or preventing cardiovascular disease in a mammal comprising the step of administering to a mammal a therapeutically effective amount of at least one compound of Claims 1-24, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.
 - 38. A method of treating or preventing syndrome X in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of Claims 1-24. or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.
 - 39. A method of treating or preventing disease or condition in a mammal selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of at least one compound of Claims 1-24 and an effective amount of second therapeutic agent selected from the group consisting of: insulin sensitizers, sulfonylureas, biguanides, thiazolidinediones, α-glucosidase inhibitors, insulin secretogogues, insulin, antihyperlipidemic agents, plasma HDL-raising agents, HMG-CoA reductase inhibitors.

statins, acryl CoA:cholestrol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin.

Use of a compound of Claims 1-24 and pharmaceutically
 acceptable salt, solvate, hydrate or stereoisomer thereof, for the manufacture of a medicament for the treatment of a condition modulated by a PPAR.